1. ALLA AKTIER
  2. NYHETER
  3. IMMUNOVIA

Immunovia

Nyheter Immunovia Nyheter alla bolag

Immunovia Selected for Presentation at EDRN Scientific Workshop in US on May 21

Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, has been selected to present its clinical data at the Scientific Workshop Poster Session of the Early Detection Research Network (EDRN), a cancer early-detection program established by the U.S. National Cancer Institute, on May 21, 2025.

This prestigious selection reflects the growing recognition of Immunovia’s scientific progress and the momentum behind its diagnostic test, PancreaSure.

This special session features selected scientific research recognized for its impact and innovation. Randall Brand MD, Professor of Medicine at the University of Pittsburgh School of Medicine and Director of the UPMC GI Malignancy Early Detection, Diagnosis and Prevention Program will present key data from the company’s CLARITI study, which aimed to clinically validate PancreaSure™, Immunovia’s blood-based early detection test for pancreatic cancer.

“Having a National Cancer Institute-formed consortium highlight our work underscores the scientific strength behind our test,” said Norma Palma PhD, Vice President of Clinical and Medical Affairs at Immunovia. “It affirms the credibility of our data and the vital need for early detection solutions in pancreatic cancer.”

The EDRN’s mission is to discover, validate, and translate biomarkers and imaging tools for the early detection of cancer. Immunovia’s selection marks a significant acknowledgment of the company’s commitment to advancing this mission through robust clinical science.

For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
 
USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
 
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.

Attachments
Immunovia Selected for Presentation at EDRN Scientific Workshop in US on May 21

Datum 2025-05-21, kl 09:30
Källa MFN
Bifogade filer
Immunovia Selected for Presentation at EDRN Scientific Workshop in US on May 21
Affiliate
100% cashback på aktiecourtage! Handla aktier på eToro och få tillbaka 100% av ditt courtage i 3 månader. Hur? Registrera dig här nu direkt för att ta del av erbjudandet.
Cashback är begränsad till högst $100. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.